Zofran Linked to Abnormal Heart Rhythm

Last Updated on June 1, 2017

Important Information

Attorneys working with ClassAction.org are no longer investigating this matter. The information here is for reference only. A list of open investigations and lawsuits can be viewed here.

Comments |

At A Glance

This Alert Affects:
Patients who took anti-nausea drug Zofran, used to prevent nausea and vomiting caused by chemotherapy, radiation and surgery.
Damages:
Research has indicated that Zofran may increase the risk of abnormal changes in the heart's electrical activity, which can lead to Torsade de Pointes, a potentially fatal heart rhythm.
Company(ies):
GlaxoSmithKline
Additional Details:
A QT interval is essentially the amount of time needed for the heart muscles to contract and recover.
Date:
The FDA released an initial safety announcement in Sept. 2011 about the potential link between Zofran and abnormal heart rhythms. The agency followed-up with a specific warning about the 32mg single intravenous dose of the drug and its potential to predispose patients to Torsade de Pointes.